Topic: Ebm

Dr. Richard Amerling criticizes the pharmaceutical industry's control over evidence-based medicine (EBM), labeling Remdesivir a "crappy drug" with no impact on mortality. He argues that pharmaceutical companies manipulate data and control the publication process to favor their products. Amerling contends that standardized guidelines create a "one size fits all" tyranny that prevents doctors from using clinical judgment or alternative treatments.